Re: Toni K. Choueiri, Thomas Powles, Laurence Albiges, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 2023;388:1767-78

Eur Urol. 2023 Oct;84(4):e93. doi: 10.1016/j.eururo.2023.06.027. Epub 2023 Jul 11.

Authors

Clara Cerrato¹, Benjamin Pradere², Maria Carmen Mir³

Affiliations

¹ University Hospital Southampton NHS Trust, Southampton, UK.
² Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France.
³ Department of Urology, University Hospital de la Ribera, Valencia, Spain. Electronic address: mirmare@yahoo.es.

PMID: 37442718
DOI: 10.1016/j.eururo.2023.06.027

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell* / drug therapy
Humans
Ipilimumab / therapeutic use
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology
Nivolumab / therapeutic use

Substances

Nivolumab
Ipilimumab
cabozantinib